2,335
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Sanofi's recently active trials. Comparator arms are excluded.
- Amlitelimab9 trials
- Dupilumab7 trials
- Belumosudil5 trials
- Lunsekimig4 trials
- Dexamethasone4 trials
- Duvakitug3 trials
Upcoming readouts
Next primary completion dates among Sanofi's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Dec 2026RESULT: A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Parti…Phase 2
- Feb 2027BRIGHTEN: Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaPhase 2
- Jul 2027VITALIZE: A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenou…Phase 3
- Jul 2027Frexcite: Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administ…Phase 3
- Jul 2027LIBRA: The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Di…Phase 3
- Sept 2027CLAROS: A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to…Phase 2
Top therapeutic areas
Conditions studied most often across Sanofi's recently active trials.
- Dermatitis Atopic8 trials
- Chronic Obstructive Pulmonary Disease4 trials
- Asthma4 trials
- Atopic Dermatitis4 trials
- Chronic Graft Versus Host Disease3 trials
- Multiple Sclerosis3 trials
Sanofi pipeline by phase
The main study drugs across 152 active trials Sanofi leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 321 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Rilzabrutinib | 7 | 4 | Nov 2026 est. | NCT07216079 · NCT07190196 · NCT07086976 |
| Amlitelimab | 6 | — | Sept 2026 est. | NCT06407934 · NCT06241118 · NCT06557772 |
| Frexalimab | 6 | 3 | Dec 2026 est. | NCT07325292 · NCT06141486 · NCT06141473 |
| Lunsekimig | 6 | 2 | Jun 2027 est. | NCT07793409 · NCT07190222 · NCT07190209 |
| Duvakitug | 5 | 4 | May 2028 est. | NCT07185009 · NCT07184996 · NCT07184944 |
| PCV21 vaccine | 5 | 1 | May 2027 est. | NCT07348692 · NCT06975878 · NCT06824194 |
| Itepekimab (SAR440340) | 4 | — | Oct 2026 est. | NCT07424144 · NCT06834360 · NCT06834347 |
| Fitusiran | 3 | 1 | Nov 2026 est. | NCT07285460 · NCT05662319 · NCT03754790 |
| venglustat (GZ402671) | 3 | — | Oct 2026 est. | NCT05280548 · NCT05206773 · NCT02843035 |
| Isatuximab SAR650984 | 2 | — | Apr 2027 est. | NCT04270409 · NCT03319667 |
| PCV21 | 2 | 1 | Dec 2026 est. | NCT07247188 · NCT06838000 |
| Riliprubart | 2 | 1 | Jul 2027 est. | NCT06290141 · NCT06290128 |
| efanesoctocog alfa (BIVV001) | 1 | — | Jan 2027 est. | NCT04644575 |
| Isatuximab SC | 1 | — | — | NCT05405166 |
| MenACYW conjugate vaccine | 1 | — | — | NCT07135986 |
| Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine | 1 | — | — | NCT04936685 |
| MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA) | 1 | 1 | Mar 2028 est. | NCT07710872 |
| Riliprubart Prefilled Pen (PFP) | 1 | — | Oct 2029 est. | NCT06859099 |
| Tolebrutinib | 1 | — | Apr 2029 est. | NCT06372145 |
| Venglustat | 1 | — | — | NCT05222906 |
| Yellow fever vaccine (live) | 1 | 1 | — | NCT07103148 |
Phase 220 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| BrivekimigSAR442970 | 4 | 3 | Dec 2026 est. | NCT07170917 · NCT06975722 · NCT06958536 |
| BalinatunfibSAR441566 | 3 | — | Sept 2026 est. | NCT07222189 · NCT06867094 · NCT06637631 |
| Isatuximab | 2 | 1 | Sept 2027 est. | NCT05704049 · NCT04643002 |
| SAR441344 IV | 2 | — | — | NCT05039840 · NCT04879628 |
| SAR445877 | 2 | 2 | Jan 2027 est. | NCT07692204 · NCT05584670 |
| Yellow fever vaccine (produced on serum-free Vero cells) | 2 | — | — | NCT05011123 · NCT04942210 |
| Acne mRNA (messenger ribonucleic acid) vaccine | 1 | — | Jul 2028 est. | NCT07756957 |
| Bivalent RSV+HMPV protein vaccine | 1 | — | Jul 2028 est. | NCT07810010 |
| BIVV020 (SAR445088) | 1 | — | — | NCT05156710 |
| Blood draw for the laboratory assessment | 1 | — | Jun 2031 est. | NCT02065011 |
| Isatuximab intravenous (IV) | 1 | — | Nov 2028 est. | NCT05669989 |
| Isatuximab SC-OBDS | 1 | 1 | Jan 2027 est. | NCT06356571 |
| Long term follow up in all patients who received SAR422459 in previous study TDU13583 | 1 | — | Aug 2033 est. | NCT01736592 |
| Rilzabrutinib dose 1 | 1 | 1 | — | NCT06984627 |
| SAR443122 | 1 | — | — | NCT05588843 |
| SAR444336 | 1 | 1 | Apr 2027 est. | NCT07156175 |
| SAR445399 | 1 | 1 | Sept 2027 est. | NCT07225569 |
| SAR447537 | 1 | — | Jun 2028 est. | NCT05897424 |
| SAR448851 | 1 | 1 | Jul 2029 est. | NCT07688213 |
| Sarilumab SAR153191 (REGN88) | 1 | 1 | Mar 2028 est. | NCT02991469 |
Phase 119 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Acne mRNA vaccine | 2 | 2 | Nov 2028 est. | NCT07013747 · NCT06316297 |
| SAR448501 | 2 | 2 | Jan 2028 est. | NCT06647069 · NCT06392477 |
| Chlamydia mRNA Vaccine | 1 | 1 | Jan 2028 est. | NCT06891417 |
| Dupilumab coformulated with berahyaluronidase alfa | 1 | — | Sept 2026 est. | NCT07646548 |
| Flu H5 egg pandemic low dose vaccine, with adjuvant | 1 | 1 | Feb 2028 est. | NCT07779408 |
| H5 Flu Investigational Medical Product (IMP) 1 | 1 | 1 | Apr 2027 est. | NCT07516418 |
| Investigational hMPV/RSV vaccine | 1 | — | Jan 2027 est. | NCT06686654 |
| Pandemic flu H5 HA mRNA SD2 vaccine | 1 | — | Dec 2026 est. | NCT06907511 |
| Pentavalent Meningococcal ABCYW vaccine | 1 | — | May 2027 est. | NCT06647407 |
| RSV+HMPV vaccine | 1 | 1 | May 2028 est. | NCT07734649 |
| SAR402663 | 1 | — | May 2027 est. | NCT06660667 |
| SAR444836 | 1 | — | Apr 2030 est. | NCT05972629 |
| SAR446268 | 1 | 1 | Feb 2029 est. | NCT06844214 |
| SAR446523 | 1 | 1 | May 2031 est. | NCT06630806 |
| SAR446597 | 1 | 1 | Oct 2027 est. | NCT07215234 |
| SAR447971 | 1 | 1 | Feb 2028 est. | NCT07629336 |
| Sarilumab, SAR153191 SC | 1 | 1 | Oct 2028 est. | NCT07704580 |
| trivalent (RSV/hMPV/PIV3) vaccine candidate | 1 | — | — | NCT07295028 |
| VXB-241 60 mcg (Low Dose) | 1 | — | — | NCT06556147 |
Phase 410 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Dupilumab | 16 | 7 | Sept 2026 est. | NCT07053423 · NCT06101095 · NCT05983068 |
| Belumosudil | 6 | 2 | Sept 2026 est. | NCT07135973 · NCT07771439 · NCT06143891 |
| teplizumab | 3 | 2 | Mar 2028 est. | NCT05757713 · NCT07088068 · NCT06791291 |
| Avalglucosidase alfa | 2 | 1 | May 2028 est. | NCT06666413 · NCT04910776 |
| Avalglucosidase alfa (GZ402666) | 2 | — | Jun 2027 est. | NCT05164055 · NCT03019406 |
| Efanesoctocog alfa | 1 | 1 | Oct 2027 est. | NCT06941870 |
| Fitusiran (SAR439774) | 1 | 1 | May 2028 est. | NCT06145373 |
| iGlarLixi (insulin glargine/lixisenatide) | 1 | 1 | Sept 2026 est. | NCT06671587 |
| Nirsevimab | 1 | — | — | NCT07109297 |
| Sarilumab | 1 | 1 | Jun 2029 est. | NCT07286214 |
Derived from 152 active trials Sanofi leads; 150 name an intervention, folding into 70 phased drugs. 5 interventions carry no registry phase (observational studies, tests and devices) and are not shown. This is ComplyRx's reading of the registry, not Sanofi's own pipeline disclosure.
Sanofi trials
The 50 most significant of Sanofi's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsNCT07726914Belumosudil | Phase 1 | Not yet scored | OngoingNot yet recruiting | 58 est. | 28 Sept 2026 |
| A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)NCT07222189balinatunfib | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 325 est. | 30 Sept 2026 |
| Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsNCT07646548Dupilumab coformulated with berahyaluronidase alfa | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 40 est. | 30 Sept 2026 |
| LEAPVenglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionNCT02843035venglustat (GZ402671) | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 12 est. | 30 Oct 2026 |
| Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)NCT07457580Teplizumab | — | Not yet scored | OngoingRecruiting | 60 est. | 30 Nov 2026 |
| RESULTA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseNCT06500702frexalimab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 84 est. | 23 Dec 2026 |
| Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)NCT07038473Investigational Procedure | Na | Locked · track to reveal | OngoingRecruiting | 3,500 est. | 25 Dec 2026 |
| XTEND-edLong-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia ANCT04644575efanesoctocog alfa (BIVV001) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 261 est. | 15 Jan 2027 |
| BRIGHTENBrivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaNCT07170917Brivekimig | Phase 2 | Locked · track to reveal | OngoingRecruiting | 208 est. | 9 Feb 2027 |
| CEREN-3An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal PolypsNCT07424144Itepekimab (SAR440340) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 59 est. | 17 Feb 2027 |
| GLOBOSTADObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)NCT03992417Dupilumab SAR231893 (REGN668) | — | Locked · track to reveal | OngoingActive, not recruiting | 955 est. | 31 Mar 2027 |
| FREXALTEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473Frexalimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,655 est. | 6 May 2027 |
| ORBIT-CIDPReal-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)NCT06968975 | — | Not yet scored | OngoingRecruiting | 200 est. | 17 May 2027 |
| A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular DegenerationNCT06660667SAR402663 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 66 est. | 18 May 2027 |
| DERMIND-ADThe Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic DermatitisNCT07467564Dupilumab | — | Locked · track to reveal | OngoingRecruiting | 184 est. | 24 May 2027 |
| Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)NCT05164055Avalglucosidase alfa (GZ402666) | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 17 est. | 30 Jun 2027 |
| VITALIZEA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT06290141riliprubart | Phase 3 | Locked · track to reveal | OngoingRecruiting | 160 est. | 9 Jul 2027 |
| FrexciteNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisNCT07325292Frexalimab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 160 est. | 15 Jul 2027 |
| LIBRAThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseNCT06975865Rilzabrutinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 192 est. | 23 Jul 2027 |
| CLAROSA Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT07225569SAR445399 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 144 est. | 22 Sept 2027 |
| AQUAA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorNCT06241118Amlitelimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 464 est. | 30 Sept 2027 |
| CEREN-4A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT07484230Itepekimab (SAR440340) | Phase 3 | Locked · track to reveal | StoppedWithdrawn | 0 est. | 20 Oct 2027 |
| A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis BronchiectasisNCT07547436SAR445399 | Phase 2 | Locked · track to reveal | OngoingSuspended | 70 est. | 29 Oct 2027 |
| Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of KoreaNCT07621653Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine | — | Not yet scored | OngoingRecruiting | 706 est. | 23 Nov 2027 |
| Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.NCT07779408Flu H5 egg pandemic low dose vaccine, with adjuvant | Phase 1 | Locked · track to reveal | OngoingRecruiting | 640 est. | 22 Feb 2028 |
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in ChinaNCT07710872MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA) | Phase 3 | Locked · track to reveal | OngoingRecruiting | 4,568 est. | 13 Mar 2028 |
| AD-BEASCUITSA Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab TreatmentNCT06192563Dupilumab | — | Locked · track to reveal | OngoingRecruiting | 230 est. | 31 Mar 2028 |
| Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and OlderNCT07734649RSV+HMPV vaccine | Phase 1 | Not yet scored | OngoingRecruiting | 2,400 est. | 3 May 2028 |
| SUNSCAPE-1An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisNCT07184996Duvakitug | Phase 3 | Locked · track to reveal | OngoingRecruiting | 980 est. | 9 May 2028 |
| LUMINA 3A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic AnemiaNCT07086976rilzabrutinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 90 est. | 31 May 2028 |
| βETA PRESERVEA Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068Teplizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 723 est. | 6 Jun 2028 |
| AURALIGHTA Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT07812116Duvakitug | Phase 2 | Not yet scored | OngoingNot yet recruiting | 156 est. | 16 Jun 2028 |
| RILIEFA 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related DiseaseNCT07190196Rilzabrutinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 124 est. | 28 Jun 2028 |
| Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and OlderNCT07810010Bivalent RSV+HMPV protein vaccine | Phase 2 | Not yet scored | OngoingRecruiting | 8,000 est. | 3 Jul 2028 |
| Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe AcneNCT07756957Acne mRNA (messenger ribonucleic acid) vaccine | Phase 2 | Not yet scored | OngoingNot yet recruiting | 410 est. | 19 Jul 2028 |
| A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction CancerNCT07692204SAR445877 | Phase 2 | Not yet scored | OngoingRecruiting | 30 est. | 2 Aug 2028 |
| SUNSCAPE-2A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisNCT07185009Duvakitug | Phase 3 | Locked · track to reveal | OngoingRecruiting | 751 est. | 21 Sept 2028 |
| schoolROCKA Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)NCT07116031Belumosudil | Phase 2 | Locked · track to reveal | OngoingRecruiting | 37 est. | 25 Sept 2028 |
| OPALSPhase 1b/2 Study of IV Sarilumab in Adult With RANCT07704580Sarilumab, SAR153191 SC | Phase 1 | Not yet scored | OngoingRecruiting | 140 est. | 26 Oct 2028 |
| Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe AcneNCT06316297Acne mRNA vaccine | Phase 1 | Locked · track to reveal | OngoingRecruiting | 800 est. | 30 Nov 2028 |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabNCT05669989Isatuximab intravenous (IV) | Phase 2 | Locked · track to reveal | OngoingEnrolling by invitation | 70 est. | 30 Nov 2028 |
| Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)NCT06191315Dupilumab | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 90 est. | 21 Dec 2028 |
| A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)NCT06192576Olipudase alfa | — | Not yet scored | OngoingRecruiting | 10 est. | 2 Jan 2029 |
| RIVER-ADLong-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsNCT05492578Amlitelimab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 1,856 est. | 22 Jan 2029 |
| AIRITYA Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical PracticeNCT07556159Procedure: Investigational Procedures | — | Not yet scored | OngoingRecruiting | 2,500 est. | 4 Apr 2029 |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145Tolebrutinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 2,500 est. | 30 Apr 2029 |
| A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic DiseasesNCT06647069SAR448501 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 62 est. | 25 Jun 2029 |
| STRIDEThe Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) RegistryNCT07612878Cohort 1: Dupilumab | — | Locked · track to reveal | OngoingRecruiting | 350 est. | 30 Jun 2029 |
| TREMHANCEA Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's DiseaseNCT07688213SAR448851 | Phase 2 | Not yet scored | OngoingRecruiting | 160 est. | 31 Jul 2029 |
| ATLAS-KIDSA Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BNCT07285460Fitusiran | Phase 3 | Locked · track to reveal | OngoingRecruiting | 85 est. | 4 Aug 2029 |